Erratum: IncobotulinumtoxinA for the treatment of lower-limb spasticity in children and adolescents with cerebral palsy: A phase 3 study (Journal of Pediatric Rehabilitation Medicine (2021) 14: 2 (183-197) DOI: 10.3233/PRM-210040)

On page 189, under the topic 3.1.1, in the first sentence, significance is incorrectly attributed to the data shown in Fig 3. Significance data were obtained from MMRM analyses. The sentence should read as follows: "Patients in all three incobotulinumtoxinA dose groups (total body doses of 4, 8, and 16 U/kg [maximum 100, 300, and 400 U]) experienced improvements in AS-PF scores on the primary body side chosen for treatment 4 weeks post-injection in injection cycle 1 versus the study baseline (Fig. 3) that were significant in MMRM analyses (p < 0.0001 for all)." On page 190, under the topic 3.1.1, in the fourth sentence, significance by ANCOVA analyses is not mentioned. The sentence should read as follows: "Likewise, investigator's GICS-PF scores indicated a clinically meaningful response to incobotulinumtoxinA treatment in all dose groups 4 weeks post-injection in injection cycle 1 (Fig. 4) that were significant in ANCOVA analyses (p < 0.0001 for all doses in injection cycle 1, and also in injection cycle 2)." On page 190, under the section 3.1.2.1, in the second sentence, significance by MMRM analyses is not mentioned. The sentence should read as follows: "AS-PF scores of the primary body side further improved from baseline to week 4 of the second injection cycle in all three dose groups (Fig. 3); improvements were significant versus baseline in MMRM analyses (p < 0.0001 for all doses)." On page 190, under the section 3.1.2.1, in the fourth sentence, significance by MMRM analyses is not mentioned. The sentence should read as follows: "Following unilateral LL treatment, all doses of incobotulinumtoxinA resulted in improvements from baseline in AS scores of the knee flexors (Fig. 5A) and the thigh adductors (Fig. 5B) 4 weeks following each injection; improvements in knee flexors were significant in MMRM analyses for the high dose group in injection cycle 1 and 2 and for the low dose group in injection cycle 2 (p < 0.01).".